CHILDREN'S NASACORT ALLERGY 24HR OTC
Generic Name and Formulations:
Triamcinolone acetonide 55mcg; per nasal spray; scent- and alcohol-free.
Indications for CHILDREN'S NASACORT ALLERGY 24HR:
Seasonal and perennial allergic rhinitis, including nasal congestion.
2 sprays in each nostril once daily. Reduce dose as symptoms improve.
<2yrs: not recommended. 2–<6yrs: 1 spray in each nostril once daily. 6–12yrs: 1 spray in each nostril once daily; max 2 sprays in each nostril once daily. Reduce dose as symptoms improve.
Avoid use in patients with recent nasal ulcers, surgery, or injury that has not healed. Infections (eg, ocular herpes simplex). Glaucoma. Cataracts. Discontinue if exposed to measles, chickenpox, or tuberculosis. Monitor for growth suppression in children. Avoid eyes or mucous membranes. Reevaluate if no improvement after 1 week. Pregnancy. Nursing mothers.
Avoid concomitant other steroid-containing products.
Infection, fever, visual changes, severe or frequent nosebleeds.
Nasal Spray—8.25g (60 sprays), 16.5g (120 sprays); Children's—8.25g (60 sprays)
Clinical Pain Advisor Articles
- Opioids: Clinician Concern and Prescribing Practices
- Quantity of Opioids Prescribed Linked to Higher Patient-Reported Consumption
- Screening for Hyperglycemia Prior to Steroid Injections for Chronic Pain
- Ensuring Safety During Long-Term Opioid Therapy
- Drug Overdose Mortality Rates Rising in the United States
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- Tips Provided for Budgeting in Medical Residency
- Give Thanks: The Role of Gratitude in Combating Burnout
- Persistent Back Pain Linked to Earlier Mortality in Older Women
- Cannabinoids May Be Effective on Experimental Pain Threshold and Tolerance, Not Intensity
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain